Analyst Joseph Stringer of Needham maintained a Buy rating on Stoke Therapeutics (STOK – Research Report), retaining the price target of $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Stringer has given his Buy rating due to a combination of factors discussed during a recent meeting with Stoke Therapeutics’ management. The conversation centered around the promising developments in the pivotal Phase 3 EMPEROR trial for zorevunersen, a treatment for Dravet Syndrome, which has recently begun enrolling participants.
The analysis of the trial’s endpoints and its statistical power, along with the potential commercial success of zorevunersen in treating Dravet Syndrome, were key considerations in Stringer’s positive outlook. These elements contribute to the confidence in the stock’s future performance, justifying the Buy rating.